Search
Cycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Manidipine
go.drugbank.com/drugs/DB09238ApprovedInvestigationalWithdrawnIt is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigationalMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … cutaneous T-cell lymphoma.
Categories: Chemokine Receptor Type 4 Interaction, Chemokine Receptor Type 4 InteractionsClobetasol
go.drugbank.com/drugs/DB11750ApprovedInvestigationalWithdrawnClobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Categories: Corticosteroid Hormone Receptor AgonistsBuformin
go.drugbank.com/drugs/DB04830ApprovedWithdrawnBuformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin. … It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis.
Methoxsalen
go.drugbank.com/drugs/DB00553ApprovedInvestigationalIt is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.
Demeclocycline
go.drugbank.com/drugs/DB00618ApprovedA tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Rimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Nalidixic acid
go.drugbank.com/drugs/DB00779ApprovedWithdrawnIt is an inhibitor of the A subunit of bacterial DNA gyrase.
Ganirelix
go.drugbank.com/drugs/DB06785ApprovedInvestigational[L43045] The first case of pregnancy achieved after the use of ganirelix in an assisted reproduction program was reported in 1998.[A252195] Ganirelix was first approved by the FDA on July 29, 1999.
Categories: Gonadotropin Releasing Hormone Receptor Antagonists